Journal of Clinical Gastroenterology

Our medical research library holds 5 studies published in Journal of Clinical Gastroenterology (1997–2013). Each entry links to the study's record on PubMed and, where there is one, to the publisher's page and a free full text. 4 have an abstract, the authors' own summary as PubMed records it: open "Abstract" to read it.

About the journal

• Publisher: Wolters Kluwer Health, Inc
• Published: 1979 to the present, United States
• Language: English
• ISSN: 0192-0790 (print), 1539-2031 (electronic)
• Its record in the NLM Catalog

2010s

• Serum HMGB1 as a diagnostic marker for malignant peritoneal mesothelioma. C. Tabata, S. Kanemura, R. Tabata, et al. 2013;47(8):684-8. PubMed · Publisher

  Abstract

  Background: Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive malignant tumor of mesothelial origin that shows a limited response to cytoreductive surgery along with intraperitoneal chemotherapy. Therefore, early diagnosis of DMPM is very important. Some researchers have previously reported that high-mobility group box 1 (HMGB1) was correlated with pulmonary fibrosis. DMPM involves the malignant transformation of mesothelial cells, which originate from mesenchymal cells, similar to lung fibroblasts. Here, we investigated serum levels of HMGB1 in patients with MPM and compared them with those of a population that had been exposed to asbestos without developing MPM.

  Study: The serum concentrations of HMGB1 were measured in 13 DMPM patients and 45 individuals with benign asbestos-related diseases.

  Result: We demonstrated that the patients with DMPM had significantly higher serum levels of HMGB1 compared with the population who had been exposed to asbestos but did not develop DMPM.

  Conclusion: Our data suggest that serum HMGB1 concentration is a useful serum marker for DMPM.

• Serum thioredoxin-1 as a diagnostic marker for malignant peritoneal mesothelioma. C. Tabata, T. Terada, R. Tabata, et al. 2013;47(1):e7-11. PubMed · Publisher

  Abstract

  Background: Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive malignant tumor of mesothelial origin that shows a limited response to cytoreductive surgery along with intraperitoneal chemotherapy. Therefore, diagnosing DMPM early is very important. Reactive oxygen species play an important role in asbestos toxicity, which is associated with the pathogenesis of DMPM growth. Thioredoxin-1 (TRX) is a small redox-active protein that demonstrates antioxidative activity associated with tumor growth. Here, we investigated the serum levels of TRX in patients with DMPM and compared them with those of a population that had been exposed to asbestos but did not have DMPM.

  Study: The serum concentrations of TRX were measured in 15 DMPM patients and 34 individuals with benign asbestos-related diseases.

  Results: We demonstrated that the patients with DMPM had significantly higher serum levels of TRX than the population that had been exposed to asbestos but did not have DMPM.

  Conclusions: Our data suggest that serum TRX concentration is a useful serum marker for DMPM.

2000s

• Peritoneal mesothelioma associated with exposure to asbestos in southeastern Turkey. H. Değertekin, K. Yalçin, R. Işik. 2002;35(5):409. Letter PubMed · Publisher

• Recurrent peritoneal mesothelioma with long-delayed recurrence. A. Tandar, G. Abraham, J. Gurka, et al. 2001;33(3):247-50. Case report · Review PubMed · Publisher

  Abstract

  Peritoneal mesothelioma is a rare malignancy with a poor prognosis. Etiology is unclear and presentation of this disease is often atypical. There are very few cases of long-term survival in patients with peritoneal mesothelioma. We report the case of a patient with peritoneal mesothelioma of 19 years' duration. To the best of our knowledge, there have been no reports of recurrent peritoneal mesothelioma with such long-delayed recurrence and survival. Recurrent peritoneal mesothelioma in the current patient was confirmed by comparing the biopsies of omentum taken in 1979 with that taken in 1997. An extensive literature search was undertaken to look for previous reports of recurrent peritoneal mesothelioma. Aggressive and intensive chemotherapy appeared to provide a longer survival time. Our patient had paraneoplastic manifestations that included paraneoplastic hepatopathy and a wasting syndrome. Peritoneal mesothelioma is a rare malignancy with one to two cases per million in the United States. It is known to exhibit unusual paraneoplastic manifestations, including paraneoplastic hepatopathy. Treatment is often unsuccessful, with a median survival time of approximately 18 months from diagnosis. A better understanding and aggressive management of this disease appear to help prolong survival.

1990s

• Peritoneal mesothelioma in recurrent familial peritonitis. N. Gentiloni, S. Febbraro, C. Barone, et al. 1997;24(4):276-9. Case report · Review PubMed · Publisher

  Abstract

  A 39-year-old man had a 2-year history of fatigue, weight loss, drug-resistant ascites, and decreased intestinal motility. During adolescence he began to suffer frequent episodes of acute benign peritonitis that spontaneously subsided at age 35. The fact that his younger brother was taking colchicine for the same symptoms led us to diagnose familial Mediterranean fever (FMF). The medical workup revealed uniform thickening of the intestinal wall with no signs of amyloidosis. Exploratory laparotomy revealed diffuse peritoneal mesothelioma that proved to be unresponsive to chemotherapy. There was no history of asbestos exposure. It is probable that the chronic peritoneal inflammation was responsible for the development of this tumor, although in almost all cases of FMF this phenomenon causes only limited peritoneal fibrosis or, less commonly, encapsulating peritonitis. A computerized search of the literature indicates that this is the second report of peritoneal mesothelioma associated with FMF.

Browse every journal in the library or the library by type of article, or return to medical research.